Certified by Founder Lodge
Marshall Wace
United Kingdom - London
INVESTOR
1 Disclosed Funding Rounds $120,000,000
8 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Founded in 1997, Marshall Wace is a global asset manager offering a diverse set of alternative, long-only and bespoke investment solutions to a broad range of investors.
| Company | Date | Round | Raised |
|---|---|---|---|
 Turtlemint |
April, 29 ,2022 | Series E | $120,000,000 |
 Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
 Prognos Health |
May, 18 ,2023 | Unknown | $23,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Beta Bionics |
September, 04 ,2023 | Series D | $100,000,000 |
 BlueWhale Bio |
September, 08 ,2023 | Unknown | $18,000,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
 Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
OTPLESS | $3,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
Aeropay | $20,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
